Pharmacogenetics of Warfarin Elimination and its Clinical Implications
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Warfarin is one of the most widely prescribed oral anticoagulants. However, optimal use of the drug has been hampered by its >10-fold interpatient variability in the doses required to attain therapeutic responses. Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients. Clinically available warfarin is a racemic mixture of (R)- and (S)-warfarin, and the (S)-enantiomer has 3 to 5 times greater anticoagulation potency than its optical congener. Both enantiomers are eliminated extensively via hepatic metabolism with low clearance relative to hepatic blood flow. CYP2C9 is almost exclusively responsible for the metabolism of the pharmacologically more active (S)-enantiomer. Several human allelic variants of CYP2C9 have been cloned, designated as CYP2C9*1 (reference sequence or wild-type allele), CYP2C9*2, CYP2C9*3 and CYP2C9*4, respectively. The allelic frequencies for these variants differ considerably among different ethnic populations. Caucasians appear to carry the CYP 2C9*2 (8 to 20%) and CYP2C9*3 (6 to 10%) variants more frequently than do Asians (0% and 2 to 5%, respectively). The metabolic activities of the CYP2C9 variants have been investigated in vitro. The catalytic activity of CYP2C9*3 expressed from cDNA was significantly less than that of CYP2C9*1. Human liver microsomes obtained from individuals heterozygous for CYP2C9*3 showed significantly reduced (S)-warfarin 7-hydroxylation as compared with those obtained from individuals genotyped as CYP2C9*1. The influence of the CYP2C9*3 allele on the in vivo pharmacokinetics of (S)-warfarin has been studied in Japanese patients. Patients with the homozygous CYP2C9*3 genotype, as well as those with the heterozygous CYP2C9*1/*3 genotype, had significantly reduced clearance of (S)-warfarin (by 90 and 60%, respectively) compared with those with homozygous CYP2C9*1. The maintenance dosages of warfarin required in Japanese patients with heterozygous and homozygous CYP2C9*3 mutations were significantly lower than those in patients with CYP2C9*1/*1. In addition, 86% of British patients exhibiting adequate therapeutic responses with lower maintenance dosages of warfarin (<1.5 mg/day) had either the CYP2C9*2 or CYP2C9*3 mutation singly or in combination, whereas only 38% of randomly selected patients receiving warfarin carried the corresponding mutations. Furthermore, the former group showed more frequent episodes of major bleeding associated with warfarin therapy. These data indicate that the CYP2C9*3 allele may be associated with retarded elimination of (S)-warfarin and the resulting clinical effects. However, relationships between CYP2C9 genotype, enzyme activity, metabolism of probe substrates, dosage requirements and bleeding complications should be interpreted with caution, and further studies are required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Human-specific cytochrome P450 polymorphisms, such as CYP2C19-mediated omeprazole metabolism [19] and CYP2C9-dependent warfarin elimination [20], can cause human clearance to deviate markedly from allometric predictions.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [20]
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Gotoh, O. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48462-1 · Cited by 1,194
Applied pharmacokinetics : principles of therapeutic drug monitoring
Evans, W. E., Schentag, J. J., & Jusko, W. J. (1992) · Medical Entomology and Zoology · Cited by 1,044
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Research works printed but not linked: 8
- Kunze, 1996, Drug Metab Dispos, 24, 429
- Abernethy, 1991, J Pharmacol Exp Ther, 257, 411
- Shimada, 1994, J Pharmacol Exp Ther, 270, 414
- Schwarz, 2000, Clin Pharmacol Ther, 67, 169
- Gaedigk, 2000, Clin Pharmacol Ther, 67, 168
- Cascorbi, 1998, Clin Pharmacol Ther, 65, 198
- Shintani, 2000, Xenobio Metab Dispos, 15, S307
- Stearns, 1995, Drug Metab Dispos, 23, 207
Cited by
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Crystal structure of human cytochrome P450 2C9 with bound warfarin
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinković, D., & Jhoti, H. (2003) · Nature · doi:10.1038/nature01862 · Cited by 821
Metadata
- Authors
- Takahashi, H., & Echizen, H.
- Affiliations
- Meiji Pharmaceutical University (JP)
- Corresponding author
- Takahashi, Harumi
- ORCID
- Takahashi, Harumi
- Venue
- Clinical Pharmacokinetics
- Published
- 2001
- Volume
- 40
- Issue
- 8
- Pages
- 587-603
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2073073931
- Cited by
- 312
- References
- 71
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 9 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 11 · 2013: 12 · 2012: 20
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Research Foundation for Clinical Pharmacology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- warfarin, pharmacogenetics, CYP2C9, cytochrome P450 polymorphisms, S-warfarin, CYP2C9*3, CYP2C9*2, pharmacokinetics, ethnic differences
- MeSH terms
- Anticoagulants, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System, Genotype, Half-Life, Humans, Metabolic Clearance Rate, Microsomes, Liver, Pharmacogenetics, Polymorphism, Genetic, Stereoisomerism, Steroid Hydroxylases, Genetic Variation, Warfarin, Area Under Curve, Steroid 16-alpha-Hydroxylase, Cytochrome P-450 CYP2C9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics of Warfarin Elimination and its Clinical Implications. https://app.cochat.ai/papers/10.2165/00003088-200140080-00003
- The paper
- Takahashi, H., & Echizen, H. (2001). Pharmacogenetics of Warfarin Elimination and its Clinical Implications. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200140080-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.